Search results | biogen idec


Partnering Agreements with Biogen Idec

This report provides all the information you require to better understand Biogen Idec and its partnering interests and activities over the past seven years.


Biogen Idec

Biogen Idec is a top pharmaceutical/biotechnology company based in Weston, MA, USA

Biogen Idec: M&A activity 2005-2013

Biogen Idec has announced 5 M&A deals since 2005, with the lead deals being the acquisition of Stromedix

Biogen Idec: Partnering activity 2005-2013

Biogen Idec announced over 70 partnering / licensing deals since 2005, with 13 deals in 2012 alone. Analysis of the partnering deals shows a strong emphasis on partnerships in oncology and central nervous system diseases

Partnering with Biogen Idec: The importance of alliances and partnerships

Biogen Idec is a top pharma/biotech company active in partnering, licensing and M&A in pharmaceuticals and biotechnology

Biogen Idec: Company Profile

Biogen Idec, a top pharmaceutical/biotech company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years

Biogen Idec: Company profile

Return to top bigbiotech  list Summary Website: Biogen Headquarters: Massachusetts, USA Ticker Symbol: BIIB (Nasdaq Stock Exchange) IDP (Frankfurt Stock Exchange) SEC Link: Biogen Subsidiaries: Biogen Biogen Idec International Biogen Idec New Ventures Conforma Therapeutics Fumapharm IDEC Pharmaceuticals Samsung Bioepis Stromedix Syntonix Pharmaceuticals Top bigbiotech ranking*: 4 *Ranking based on reported global pharma sales for year ending December more »

Biogen Idec & Isis Pharmaceuticals sign a pharma partnering drug development pact

Biogen Idec and Isis Pharmaceuticals have entered into a global pharma partnering collaboration agreement under which the companies will discover and develop antisense drugs against three undisclosed targets to treat neurological or neuromuscular disorders.

Dealmakers weekly review – July 3 2012 – Amylin, Bristol-Myers Squibb, AstraZeneca, Biogen Idec, Celgene, Inhibrx

BMS acquires Amylin and then collabroates with AstraZeneca on diabetes franchise dominates the weeks dealmaking

Dealmakers weekly review – February 27 2012 – Biogen Idec, Novartis, GSK, Merck & Co, YM Bioscience, Gilead, Galen

Partnering was down on the previous week in terms of number of deals, however a number of deals of financial significance were announced

Dealmakers weekly review – February 20 2012 – Biogen Idec, Stromedix, Tetraphase, BioGaia, Nexmed, Swedish Orphan Biovitrum

Partnering was up on the previous week in terms of number of deals, but no deals of financial significance were announced. Partnering in terms of big headline deals seems to have taken breather for the past few weeks.


Sorry, your search returned no results.


Biogen Idec enters hemophilia academic research pact

Biogen Idec, Fondazione Telethon and Ospedale San Raffaele have entered into a worldwide collaboration to jointly develop gene therapies for the treatment of both hemophilia A and B

Biogen Idec acquires Convergence Pharmaceuticals

Biogen Idec plans to leverage Convergence’s expertise in chronic pain research and clinical development to accelerate the growth of its pain portfolio

Sobi and Biogen Idec sign a pharma deal for hemophilia

Swedish Orphan Biovitrum has elected to add the preclinical rFVIIIFc-XTEN-vWF fusion molecule to the company’s pharma deal with Biogen Idec.

Eisai and Biogen Idec ink a pharma deal for Alzheimer’s disease

Eisai and Biogen Idec have entered into a pharma deal to develop and commercialize two of Eisai’s clinical candidates for Alzheimer’s disease (AD), E2609 and BAN2401.

Biogen Idec and UCB make a pharma alliance pact

Biogen Idec and UCB have signed exclusive pharma alliance agreements granting UCB the right to commercialize Biogen Idec products.

Pharma licensing deal between Biogen Idec and Sangamo

Biogen Idec and Sangamo BioSciences announced an exclusive worldwide Pharma licensing and collaboration agreement focused on the development of therapeutics for hemoglobinopathies for $320 million.

Biogen Idec forms a pharma alliances with Proteostasis Therapeutics

A pharma alliances is created between Biogen Idec and Proteostasis Therapeutics for Alzheimer’s treatment.

Biogen Idec pharma partners Amicus for Parkinson’s Disease collaboration

Amicus Therapeutics has entered a collaboration with pharma partners Biogen Idec to discover, develop and commercialize novel small molecules for the treatment of Parkinson’s disease.

Biogen Idec pharma partners Isis Pharmaceuticals in $320 million neurological disease collaboration

Biogen Idec pharma partners Isis Pharmaceuticals in a broad, multi-year collaboration to leverage antisense technology to advance the treatment of neurological diseases.

Adimab expands biotech partnering with Biogen Idec

Adimab announced an expanded biotech partnering with Biogen Idec, a big pharma company,  for the discovery of antibody based therapeutics